least annually, to personnel caring for patients or human research subjects who cannot be released under §35.75. To satisfy this requirement, the instruction must be commensurate with the duties of the personnel and include—

1. Patient or human research subject control;
2. Visitor control, including—
   a. Routine visitation to hospitalized individuals in accordance with §20.1301(a)(1) of this chapter; and
   b. Visitation authorized in accordance with §20.1301(c) of this chapter;
3. Contamination control;
4. Waste control; and
5. Notification of the Radiation Safety Officer, or his or her designee, and an authorized user if the patient or the human research subject has a medical emergency or dies.

(b) A licensee shall retain a record of individuals receiving instruction in accordance with §35.2310.

§35.315 Safety precautions.

(a) For each patient or human research subject who cannot be released under §35.75, a licensee shall—

1. Quarter the patient or the human research subject either in—
   a. A private room with a private sanitary facility; or
   b. A room, with a private sanitary facility, with another individual who also has received therapy with unsealed byproduct material and who also cannot be released under §35.75;
2. Visibly post the patient’s or the human research subject’s room with a “Radioactive Materials” sign.
3. Note on the door or in the patient’s or human research subject’s room where and how long visitors may stay in the patient’s or the human research subject’s room; and
4. Either monitor material and items removed from the patient’s or the human research subject’s room to determine that their radioactivity cannot be distinguished from the natural background radiation level with a radiation detection survey instrument set on its most sensitive scale and with no interposed shielding, or handle the material and items as radioactive waste.

(b) A licensee shall notify the Radiation Safety Officer, or his or her designee, and an authorized user as soon as possible if the patient or human research subject has a medical emergency or dies.

§35.390 Training for use of unsealed byproduct material for which a written directive is required.

Except as provided in §35.57, the licensee shall require an authorized user of unsealed byproduct material for the uses authorized under §35.300 to be a physician who—

(a) Is certified by a medical specialty board whose certification process has been recognized by the Commission or an Agreement State and who meets the requirements in paragraphs (b)(1)(i)(G) and (b)(2) of this section. (Specialty boards whose certification processes have been recognized by the Commission or an Agreement State will be posted on the NRC’s Web page.) To be recognized, a specialty board shall require all candidates for certification to:

1. Successfully complete residency training in a radiation therapy or nuclear medicine training program or a program in a related medical specialty. These residency training programs must include 700 hours of training and experience as described in paragraphs (b)(1)(i)(G) and (b)(2) of this section. Eligible training programs must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education, the Royal College of Physicians and Surgeons of Canada, or the Committee on Post-Graduate Training of the American Osteopathic Association; and
2. Pass an examination, administered by diplomates of the specialty board, which tests knowledge and competence in radiation safety, radioisotope handling, quality assurance, and clinical use of unsealed byproduct material for which a written directive is required; or

(b)(1) Has completed 700 hours of training and experience, including a minimum of 200 hours of classroom and laboratory training, in basic radioisotope handling techniques applicable